You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

384 Results
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
PACLitaxel,
trastuzumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2026
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
cytarabine,
quizartinib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2026
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
quizartinib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2026
Regimen
Cancer Type:
Gynecologic, 
Cervix
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Pembrolizumab - In Combination with Chemoradiotherapy for Locally Advanced Cervical Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2026
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Curative
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2026
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2026
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2026
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2026
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2026
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative, Palliative
Funding:
New Drug Funding Program
    Dostarlimab - Primary Advanced or Recurrent MSI-H or dMMR Endometrial Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
dostarlimab,
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2026
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
DOXOrubicin,
bleomycin,
vinBLAStine,
dacarbazine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet
Updated
Feb 2026
Regimen
Cancer Type:
Central Nervous System
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    vorasidenib - For the treatment of Grade 2 astrocytoma or oligodendroglioma in patients with a susceptible IDH1 mutation or IDH2 mutation following surgery, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
vorasidenib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Mar 2026

Pages